Abstract: Large intelligent surfaces (LISs) with sparse channel sensors are provided. Embodiments described herein provide efficient solutions for these problems by leveraging tools from compressive sensing and deep learning. Consequently, an LIS architecture based on sparse channel sensors is provided where all LIS elements are passive reconfigurable elements except for a few elements that are active (e.g., connected to baseband). Two solutions are developed that design LIS reflection matrices with negligible training overhead. First, compressive sensing tools are leveraged to construct channels at all the LIS elements from the channels seen only at the active elements. These full channels can then be used to design the LIS reflection matrices with no training overhead.

Abstract: The present invention provides a method of imaging a subject's lung which comprises contacting the subject's lung with a matrix metalloproteinase inhibitor labeled with a radioisotope under conditions such that the inhibitor binds to matrix metalloproteinase in the lung, and then imaging the radiolabeled inhibitor bound to matrix metalloproteinase in the subject's lung. The invention also provides Ro 32-3555 labeled with a radioisotope.

Abstract: The summary of the present invention is a portable autonomous device and method operating independently of the aircraft flight control equipment. The device can be easily moved from one aircraft to another. The device measures the acceleration of the aircraft from the instantaneous speed and the runway distance covered from the start of the acceleration. Once the runway length and take-off speed is input, the device calculates the remaining distance to safely reach the take-off speed. If the remaining runway distance is not enough for the safe take-off, the device provides visual or audible information about the situation and signals to the pilot. In other embodiments, the determination and presentation of the remaining runway length may be implemented in the aircraft flight control equipment.

Abstract: Methods of forming graphene may include reacting a dispersed mixture, comprising fly ash, a charged heteroaromatic compound, particularly a pyridinium compound, such as a 1-(4-pyridyl)-pyridinium salt, and a solvent, particularly an alcohol, such as ethanol, with a polymeric oxidizing agent, preferably polymer-supported pyridinium chlorochromate, to form a second mixture; and contacting the second mixture at a temperature of 120 to 180° C. with a gas stream comprising at least 0.1 vol. % CH4 and at least 10 vol. % H2 to form graphene on the fly ash. Methods of managing waste may comprise using fly ash waste to produce graphene. Devices for implementing such methods may involve steel cylindrical reaction vessels including a cover through which a valve-stoppable pipe is fed, which reaction vessel is at least partially surrounded by a heating device, and suitable for handling solvent and fly ash, as well as for receiving gas inflow through the pipe.

Abstract: An object of the invention is to provide a low toxicity antisense nucleic acid medicine that can modulate expression of a target transcriptional product in the central nervous system and other sites of a subject. Provided is a low toxicity composition for modulating expression of a target transcriptional product in a site such as the central nervous system of a subject, having a nucleic acid complex formed by annealing together a first nucleic acid strand having an antisense oligonucleotide region with respect to the target transcriptional product, and a second nucleic acid strand having a complementary region that is complementary to at least part of the first nucleic acid strand.

Abstract: Aspects of the disclosure provide a power conversion system and a method for conversing power. The power conversion system includes a first fluid holding tank, a second fluid holding tank, a fluid inlet hose, a fluid outlet hose, a fluid container, and one or more tension springs connected to the upper surface of the container and to a lower surface of the first fluid holding tank. The power conversion system further includes a rotational component connected to a lower side of the container via a connecting rod. The power conversion system further includes a generator connected to the rotational component via a horizontal shaft. The power conversion system further includes a feedback hose connected between the second fluid holding tank and the first fluid holding tank. The power conversion system further includes a hydraulic pump connected to the second fluid holding tank.

Abstract: The present disclosure relates to a novel chitinolytic enzyme, particularly to a chitinolytic enzyme including an exo-?-N-acetylglucosaminidase (Clocel_3193) constituting a cellulosome derived from Clostridium cellulovorans as an active ingredient. The present disclosure allows utilization of chitin biomass which has not been used formerly as a raw material and allows environment-friendly production of N-acetylglucosamine. In addition, since the Clocel_3193 has a cell wall binding ability and degrading ability, the Clocel_3193 may be used in an antifungal composition.

Abstract: A circular resonator, and an optical modulator and an optical element comprising same. The circular resonator includes a first material, formed in a circular shape, including a plurality of nano holes and having a thermo-optic coefficient varying at a predetermined ratio according to temperature, and a second material having a thermo-optic coefficient varying in a direction opposite to the direction of change of the thermo-optic coefficient of the first material depending on temperature, the second material being filled in the plurality of nano holes, wherein an interval between the plurality of nano holes is formed at a pitch shorter than the wavelength of incident light.

Abstract: The present invention is based on a novel concept for finding the optimum expression level of a therapeutic gene for inducing the largest therapeutic effect without any adverse reaction. An object of the present invention is to develop an immuno-viral therapeutic vector exerting the optimal therapeutic effect while ensuring high safety. The present invention provides, for example, an oncolytic virus comprising an immunity-inducing gene operably linked to the downstream of E2F promoter or a promoter having an activity equivalent thereto, wherein at least one promoter for nucleic acids encoding an element essential for viral replication or assembly is replaced with a promoter for an organ specific highly expressed factor or with a promoter for a cancer cell specific highly expressed factor.

Abstract: Provided herein photo-reactive inks, thermal-curable materials and objects (e.g., medical implants, scaffolds, devices, etc.) made therefrom, and methods of preparation and use thereof.

Abstract: Apparatus and methods for constructing a tomographic image of a sample are disclosed. The apparatus comprises at least one source configured to emit electromagnetic radiation at a first wavelength, at least one angularly-selective detector configured to detect the electromagnetic radiation at a second wavelength after the electromagnetic radiation has interacted with the sample, and a controller configured to construct a tomographic image of the sample based on information gathered using the at least one detector. The controller obtains information indicative of an intensity of the electromagnetic radiation detected at a second position by the at least one detector while the source is in a first position. Then, the source and detector positions are interchanged, and the controller obtains information indicative of an intensity of the electromagnetic radiation detected at the first position by the at least one detector while the electromagnetic radiation is emitted from the second position.

Abstract: An LED-driven optical cavity PCR system and method is disclosed for fast, accurate and reliable PCR based diagnostics. An optical cavity comprising two thin light absorbing metal (AU) films is used for uniform light absorption and subsequent photo thermal light-to-heat conversion is employed for PCR thermal cycling.

Abstract: An anti-icing coating is provided having low interfacial toughness (LIT) with ice. The anti-icing coating includes a polymer and a plasticizing agent. A thickness of the anti-icing coating may be less than or equal to about 100 micrometers (?m). Further, the anti-icing coating has an interfacial toughness (?ice) with ice of less than or equal to about 1 J/m2. Such an anti-icing coating may be applied to a substrate or surface of a device on which ice may form, such as aircraft, vehicles, marine vessels, outdoor equipment, snow or ice removal equipment, recreational equipment, wind turbines, telecommunications equipment, power lines, and the like. Methods of forming such anti-icing coatings are also provided.

Abstract: The present invention provides MEL-18, which is a biomarker for human epidermal growth factor receptor2 (HER2)-positive cancer and anti-HER2 therapy, and a use thereof. According to the present invention, MEL-18 is a prognostic factor or predictor for a response of subjects to an anti-HER2-targeted drug in HER2-POSITIVE cancer and may be used in companion diagnostics for HER2-targeted drugs in subjects with HER2-positive cancer. Therefore, HER2-positive cancer may be more effectively treated by overcoming resistance to HER2 therapeutic agents and enhancing therapeutic efficacy by determining whether ADAM10/17 inhibitors are administered or co-administered with HER2-targeted drugs.

Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.

Abstract: Provided herein are particles comprising a polymer substrate comprising one or more hyaluronic acid chains; and two or more peptide moieties bound directly to each hyaluronic acid chain. In some embodiments, the two or more peptide moieties comprising collagen-binding peptide (CBP) and von Willebrand binding peptide (VBP). The particles can be utilized in, e.g., methods of hemostatic treatment.

Abstract: A method and system for codec of visual feature data is provided. First protocol format visual feature data generated by an intelligent front end and a certificate identity used to uniquely identify a corresponding first protocol format are received. The first protocol format visual feature data is converted to a same type of second protocol format visual feature data according to the certificate identity. The second protocol format visual feature data is received and parsed according to the second protocol format to obtain original visual feature data that are generated by the intelligent front end and contained in the first protocol format visual feature data.

Abstract: Technology related to blockchain cybersecurity solutions and a blockchain applicability framework is disclosed. In one example of the disclosed technology, a system is configured to receive parameters for a blockchain candidate application and evaluate the parameters to determine a recommendation for types of blockchain to apply to the candidate application. The recommendation may be based on an evaluation of the parameters to determine a level of applicability of blockchain usage, a level of applicability of one or more blockchain privacy types, and a level of applicability of one or more blockchain consensus types. The system may be configured to calculate an overall percentage distribution of the levels of applicability and to output an indication of the overall percentage distribution.

Abstract: The present invention relates to a method for simply diagnosing the progress of disease condition of a Parkinson's disease patient. Provided are a method for determining Parkinson's disease using the number of one or more intestinal bacteria selected from the group consisting of Bifidobacterium, Bacteroides fragilis group, Lactobacillus brevis, and Lactobacillus plantarum subgroup and/or the total number of intestinal bacteria as a marker, and a method for determining Parkinson's disease using the blood LPS level and/or the blood LBP level of a Parkinson's disease patient as an indicator.

Abstract: An error monitoring apparatus and method are provided. The error monitoring method includes collecting an Event-Related Potential (ERP) for at least one passenger in a first mobility for a predetermined amount of time, analyzing the ERP collected for the predetermined amount of time, and transmitting error information of the first mobility to a traffic control server based on a result of analysis. The error information of the first mobility includes at least one of information on a time when the ERP is generated, a waveform of the ERP, position information of the first mobility or operation information of a second mobility, and the second mobility is different from the first mobility and has caused the ERP.